Furvent, in first-line EGFR exon 20 insertion lung cancer, reads out imminently.
ApexOnco Front Page
Recent articles
Silevertinib trial will evaluate patients with unmethylated MGMT and EGFRvIII mutations.
The company will no longer initiate a head-to-head trial of safusidenib against Voranigo.
Bristol will advance the newest pivotal trials, in first-line colorectal and gastric cancers.
As tinkering with HLA matching continues, is nearly as good as Breyanzi good enough?
But the extensively curated dataset covering its anti-PD-L1 ADC raises more questions.
Syndax’s Revuforj beats Kura in NPM1-mutated AML.
The group is expanding its mRNA-4359 trial to include first-line melanoma.
